David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies. In this Q&A conversation, the Eye Care Network ...

4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region ...

Q&A: Sally S. Ong, MD on the neighborhood-level characteristics associated with delay in surgery and loss to follow-up ...

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Zacks about ONL1204, a first-in-class Fas pathway inhibitor showing promise in ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial. Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its ...

Belite Bio has completed patient enrollment for a trial evaluating Tinlarebant, which is the first ever treatment for Stargardt Disease. Belite Bio Inc announced 1 that enrollment is completed for its ...

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience. Affecting more than 21 million people globally, DME ...

The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...

Optical coherence tomography angiography (OCTA) was performed in all participants; the choroidal and retinal changes were examined and recorded. A new study 1 from Turkey reported that during the ...

The first reported clinical results of a Phase I study following implantation of the 3-D neural interface retinal prosthesis showed it is safe in patients with end-stage retinitis pigmentosa. The ...